Professor Peter Dettmar has provided insight into the diagnosis and treatment of reflux disease to a virtual and offline conference of key opinion leaders in China.
The national academic exchange activity was jointly initiated by China Healthcare International Exchange Promotion Association and national key experts in the field of gastroesophageal reflux disease.
The annual conference was originally due to take place in Beijing in February but was postponed due to the Covid-19 pandemic.
In his presentation, Professor Dettmar highlighted recent research studies featuring Peptest, including studies into Obstructive Sleep Apnoea, Esophageal Atresia (EA) in Children, Tooth Erosion and Salivary Pepsin and a Comparison with MII-pH in GERD and LPR.
Other speakers discussing the progress of salivary pepsin and gastro-oesophageal reflux disease included Professor Duowu Zou, director of gastroenterology department and endoscopy centre of Ruijin Hospital affiliated to Medical College of Shanghai Jiaotong University, Professor Dr Serhat Bor from the reflux disease group of Izmir Egger University in Turkey and Professor Yang from the Department of Gastroenterology, the Second Affiliated Hospital of Chongqing Medical University, China.
Also participating in the conference was our Chinese distributor Maxhealth, which was delighted with the success of the symposium on the new progress of salivary pepsin and gastroesophageal reflux disease and of the high levels of interest in its demonstration of the use of Peptest to many industry experts and fellow exhibitors.
An early and objective diagnosis of reflux, such as Peptest provides, opens the door to lifestyle changes, and future treatment. Peptest can also be used after reflux treatments to assess the success or failure of any treatment.
Learn more about how Peptest can help you.